Literature DB >> 27061333

Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience.

Daisuke Araki1, Mary W Redman2, Renato Martins2,3, Keith Eaton2,3, Christina Baik2,3, Laura Chow2,3, Bernardo Goulart2,3, Sylvia Lee2,3, Rafael Santana-Davila2,3, Jay Liao2,4, Upendra Parvathaneni2,4, George Laramore2,4, Neal Futran2,5, Eduardo Mendez2,5, Amit Bhrany5, Cristina P Rodriguez2,3.   

Abstract

BACKGROUND: Postoperative cisplatin and radiation is the standard of care for high-risk squamous cell carcinoma of the head and neck (SCCHN). We have used cetuximab and radiation in the postoperative setting for patients deemed poor candidates for cisplatin.
METHODS: We retrospectively identified 40 patients who received cetuximab and radiation for resected locoregionally advanced SCCHN between 2006 and 2013 at our institution.
RESULTS: The 2-year Kaplan-Meier estimates were: overall survival (OS) 41%, recurrence-free survival (RFS) 34%, locoregional control 63%, and distant metastatic control 59%. Eastern Cooperative Oncology Group (ECOG) performance status ≥1 predicted for inferior OS (hazard ratio [HR] = 5.43; p = .003), RFS (HR = 4.07; p = .007), and locoregional control (HR = 4.92; p = .04) in multivariate analysis.
CONCLUSION: Patients with resected high-risk SCCHN treated with postoperative cetuximab and radiation have suboptimal therapeutic outcomes. Further study of the efficacy and cost-effectiveness compared to radiation alone is warranted.
© 2016 Wiley Periodicals, Inc. Head Neck 38: 1318-1323, 2016. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  cetuximab; high-risk features; locoregionally advanced; postoperative radiation; squamous cell carcinoma of the head and neck

Mesh:

Substances:

Year:  2016        PMID: 27061333     DOI: 10.1002/hed.24437

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

1.  Effectiveness of Cetuximab in Combination with Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A 1:2 Propensity Score-matched Analysis.

Authors:  Li-Rong Wu; Huan-Feng Zhu; Jianhua Xu; Xue-Song Jiang; Li Yin; Ning Jiang; Dan Zong; Fei-Jiang Wang; Sheng-Fu Huang; Xiu-Hua Bian; Jian-Feng Wu; Dan Song; Wen-Jie Guo; Ju-Ying Liu; Xia He
Journal:  J Cancer       Date:  2018-04-18       Impact factor: 4.207

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.